# Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL

> **NCT02106091** · PHASE1 · TERMINATED · sponsor: **Affimed GmbH** · enrollment: 16 (actual)

## Conditions studied

- Relapsed B-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** AFM11

## Key facts

- **NCT ID:** NCT02106091
- **Lead sponsor:** Affimed GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2018-08
- **Final completion:** 2018-09
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Non-favorable risk/benefit profile with studied dosing regimen
- **Last updated:** 2019-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02106091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02106091, "Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02106091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*